There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Humacyte Inc. (HUMA) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.0299, or 1.42%, to $2.1399. The Humacyte Inc. has recorded 11,925 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Humacyte Hosting Key Opinion Leader Webinar on Vascular Trauma: Ukrainian Surgeons Discuss Use of Human Acellular Vessels™ (HAV™) in Wartime.
As a NASDAQ listed company, HUMA falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $2.11 and fluctuated between $2.1100 as its day high and $1.9600 as its day low. The current market capitalization of Humacyte Inc. is $214.50M. A total of 0.38 million shares were traded on the day, compared to an average of 399.79K shares.
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, HUMA has seen 2 BUY and 6 SELL insider trades, representing the acquisition of 11,564 and the disposition of 1,399,460 shares. Over the last 12 months, there were 9 BUYs and 6 SELLs from insiders. Insiders purchased 156,089 shares during that period but sold 1,399,460.
In the most recent transaction, Sander Dale A. bought 20,000 shares of HUMA for 2.60 per share on Dec 16. After the transaction, the CFO and Chief Corp. Deve. Off. now owns 20,600 company shares. In a previous transaction on Dec 16, Niklason Laura E sold 239,538 shares at 2.53 per share. HUMA shares that President, CEO and Director owns now total 17,990,736.
Among the insiders who sold shares, Dougan Brady W disposed of 239,538 shares on Dec 16 at a per-share price of $2.53. This resulted in the Director holding 17,990,736 shares of HUMA after the transaction. In another insider transaction, Ayabudge LLC sold 239,538 shares at $2.53 per share on Dec 16. Company shares held by the 10% Owner now total 17,990,736.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for HUMA in the last 3 months, the mean price target is $9.63 with high estimates of $20.00 and low estimates of $2.75. In terms of 52-week highs and lows, HUMA has a high of $8.04 and a low of $2.01.
As of this writing, HUMA has an earnings estimate of -$0.21 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.19 per share and a lower estimate of -$0.23. The company reported an EPS of -$0.19 in the last quarter, which was 9.50% higher than expectations of -$0.21.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 6 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for HUMA is Overweight with a score of 4.00. A total of 5 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 1 thought it should be Sold.